AUL
MDGL icon

AlphaGrep UK Ltd’s Madrigal Pharmaceuticals MDGL Stock Holding History

AlphaGrep UK Ltd’s Portfolio MDGL Stock Details MDGL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$397K Buy
+758
New +$362K 0.11% 362

Other funds holding MDGL

BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PC
Paulson & Co New York $3.11B AUM 94.93% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AlphaGrep UK Ltd's MDGL Position: Q1 2026 in Review

AlphaGrep UK Ltd opened a new position in Madrigal Pharmaceuticals (MDGL) in Q1 2026: 758 shares worth $397K. The stake represents 0.11% of the portfolio and ranks #362 among its holdings.

379 funds tracked by Wall St. Rank hold MDGL as of Q1 2026.

  • AlphaGrep UK Ltd held 758 shares of Madrigal Pharmaceuticals worth $397K as of Q1 2026.
  • Madrigal Pharmaceuticals was a new AlphaGrep UK Ltd position in Q1 2026.
  • Madrigal Pharmaceuticals made up 0.11% of AlphaGrep UK Ltd's portfolio in Q1 2026, its #362 holding.
  • 379 funds tracked by Wall St. Rank held Madrigal Pharmaceuticals as of Q1 2026.

Based on AlphaGrep UK Ltd's 13F filing for Q1 2026, filed 13 Aug 2026.